- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00278369
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
A Pilot Study of Denileukin Diftitox in Combination With High-Dose IL-2 for Patients With Metastatic Renal Cell Carcinoma
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry tumor-killing substances directly to kidney cancer cells. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving denileukin diftitox together with interleukin-2 may kill more tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects of denileukin diftitox and interleukin-2 in treating patients with metastatic kidney cancer.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
OBJECTIVES:
Primary
- Determine the toxic effects of denileukin diftitox and high-dose interleukin-2 in patients with metastatic renal cell cancer.
Secondary
- Perform transforming growth factor (TGF)-beta promoter and TGF-beta receptor genotyping to search for variants that may be associated with tumor response to therapy.
- Determine the overall response rate (partial and complete) in patients treated with this regimen.
- Determine the time to progression in patients treated with this regimen.
OUTLINE: This is a randomized, pilot study.
The first 3 patients enrolled in the study receive high-dose interleukin-2 (IL-2) IV over 15 minutes, 3 times daily, on days 1-5 and 15-19 and denileukin diftitox IV over 15-60 minutes once daily on days 8-10. If no dose-limiting toxicity occurs after receiving denileukin diftitox, subsequent patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive denileukin diftitox (at a higher dose than for the first 3 patients enrolled in the study) IV over 15-60 minutes once daily on days -4 to -2 and high-dose IL-2 IV over 15 minutes, 3 times daily, on days 1-5 and 15-19.
- Arm II: Patients receive high-dose IL-2 as in arm I and denileukin diftitox (at a higher dose than for the first 3 patients enrolled in the study) IV over 15-60 minutes at a higher dose once daily on days 8-10.
All patients may receive additional treatment with IL-2 alone in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for at least 4 years.
PROJECTED ACCRUAL: A total of 13 patients will be accrued for this study.
Typ studie
Zápis (Aktuální)
Fáze
- Raná fáze 1
Kontakty a umístění
Studijní místa
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611-3013
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
Documented histologically confirmed metastatic renal cell carcinoma
- Clear cell histology
Disease must be measurable as defined by lesions that can be accurately measured in at least one dimension with longest diameter > 20 mm using conventional techniques or > 10 mm with spiral CT scan
- Must have at least one measurable lesion
- If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology
- Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules and palpable lymph nodes)
The following are considered nonmeasurable lesions:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Cystic lesions
- Abdominal masses not confirmed and followed by imaging techniques
- No CNS metastases
PATIENT CHARACTERISTICS:
- ECOG performance status < 2
- Life expectancy of at least 4 months
- Serum creatinine < 2.0 mg/dL OR creatinine clearance > 50 mL/min
- Total bilirubin normal
- Platelets > 100,000/mm³
- WBC > 3,500/mm³
- No evidence of congestive heart failure
- No symptoms of coronary artery disease
- No serious cardiac arrhythmias
- A pretreatment cardiac stress test must be performed within 42 days of IL-2 treatment if any cardiac symptoms are present (patients with documented ischemia on the pretreatment cardiac stress test will be excluded from the study)
Adequate pulmonary reserve
Pulmonary function tests (PFTs) must be performed within 42 days of IL-2 treatment
- FEV_1 > 2.0 liters of > 75% predicted for height and age
- Patients unable to perform PFTs will be excluded
- Women who are pregnant or lactating are not eligible
- Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study
- Negative pregnancy test
- No known HIV-positive patients
- No evidence of active infection requiring antibiotic therapy
- Must not have a contraindication to treatment with pressor agents
- Must not have any significant medical disease that, in the opinion of the investigator, may interfere with completion of the study
- No history of another malignancy within the past 5 years other than basal cell skin cancer
PRIOR CONCURRENT THERAPY:
- Recovered from all toxic effects of prior therapy
- Must not currently receive chronic medication for asthma
- No prior interleukin-2 (IL-2) therapy
- No prior organ allografts
- No systemic corticosteroids in the 4 weeks prior to treatment
- No concurrent systemic steroids
- No radiotherapy, chemotherapy, or immunotherapy in the 4 weeks prior to the first dose of study treatment
- No concurrent radiotherapy, chemotherapy, or other immunotherapy
- No previous investigational agent within 4 weeks prior to the start of study treatment
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: A
6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
|
The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment.
IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5).
A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19).
This is one complete cycle (days 1-19) of IL-2 treatment
Ostatní jména:
Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
Ostatní jména:
|
Experimentální: B
9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
|
The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment.
IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5).
A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19).
This is one complete cycle (days 1-19) of IL-2 treatment
Ostatní jména:
Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
Ostatní jména:
|
Experimentální: C
9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
|
The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment.
IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5).
A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19).
This is one complete cycle (days 1-19) of IL-2 treatment
Ostatní jména:
Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
The primary objective is to assess for toxicity
Časové okno: After each cycle of therapy and 30 days after the last treatment.
|
To assess the toxicity
|
After each cycle of therapy and 30 days after the last treatment.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
The secondary objectives are to investigate differences in peak and duration of the expansion of CD4+, CD8+, CD4+CD 25+ and CD56+(dim and bright)CD25+ cells
Časové okno: Follow-up measurements must have met the SD criteria at least once after study entry at a minimum interval of 8 weeks.
|
To investigate differences in peak and duration.
|
Follow-up measurements must have met the SD criteria at least once after study entry at a minimum interval of 8 weeks.
|
To investigate the effects of denileukin diftitox in combination with IL-2 on plasma TGF-beta levels
Časové okno: Cohort 1: Denileukin diftitox dose of 6μg/kg/ Days 1, 2, 3, 4, and 5. Cohort 2 Denileukin diftitox dose of 9μg/kg given 4, 3, 2, and 1 days prior to 1st day of each cycle. Cohort 3: Denileukin diftitox dose of 9μg/kg given days 8 and 9.
|
To investigate the effects of denileukin diftitox
|
Cohort 1: Denileukin diftitox dose of 6μg/kg/ Days 1, 2, 3, 4, and 5. Cohort 2 Denileukin diftitox dose of 9μg/kg given 4, 3, 2, and 1 days prior to 1st day of each cycle. Cohort 3: Denileukin diftitox dose of 9μg/kg given days 8 and 9.
|
To perform TGF-beta promoter and TGF-beta receptor genotyping prior to the start of treatment to search for variants that may be associated with tumor response to therapy.
Časové okno: Cohort 1: Plasma TGF-beta levels to be given on day. Cohort 2: plasma TGF-beta levels to be given at day 1. Cohort 3: plasma TGF-beta levels given on days 1 through 5.
|
To perform TGF-beta promoter and TGF-beta receptor genotyping
|
Cohort 1: Plasma TGF-beta levels to be given on day. Cohort 2: plasma TGF-beta levels to be given at day 1. Cohort 3: plasma TGF-beta levels given on days 1 through 5.
|
Overall response rate and time to progression
Časové okno: CT scans and other pertinent studies will be performed at week 10 to assess response.
|
Overall response rate will be assessed.
|
CT scans and other pertinent studies will be performed at week 10 to assess response.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary
- Urologické novotvary
- Urogenitální novotvary
- Novotvary podle místa
- Onemocnění ledvin
- Urologická onemocnění
- Novotvary ledvin
- Fyziologické účinky léků
- Antiinfekční látky
- Agenti periferního nervového systému
- Antivirová činidla
- Anti-HIV činidla
- Antiretrovirová činidla
- Analgetika
- Agenti smyslového systému
- Analgetika, nenarkotika
- Antineoplastická činidla
- Aldesleukin
- Interleukin-2
- Denileukin diftitox
Další identifikační čísla studie
- NU 04U1
- P30CA060553 (Grant/smlouva NIH USA)
- NU-04U1
- STU00006770 (Jiný identifikátor: Northwestern University IRB)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .